Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01543763 · ClinicalTrials.gov registry record · Phase 1
Pazopanib in Combination With PCI-24781 in Patients With Metastatic Solid Tumors
A Phase 1 study, sponsored by Pamela Munster.
- Completed
- Registry status
- Phase 1
- Development phase
- 90
- Enrollment target
NCT01543763 is a Phase 1 study that has completed, run by Pamela Munster. The registered enrollment target is 90 participants.
The verdict
NCT01543763, a Phase 1 study, has completed, sponsored by Pamela Munster.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 90 participants
- Enrollment target
Study Summary
This is a open-label non-randomized, dose escalation and expansion Phase Ia/Ib study to determine the safety, tolerability and maximum tolerated dose (MTD) of pazopanib in combination with PCI-24781 in patients with advanced solid tumors.
Interventions
- DRUG PZP115891, PCI-24781
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 90 participants |
| Start Date | 2012-06-25 |
| Est. Completion | 2024-12-31 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01543763
The ClinicalTrials.gov registry entry for NCT01543763 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 90 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Pamela Munster, which has 5 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which PZP115891, PCI-24781 is the first listed.
NCT01543763 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01543763 about?
NCT01543763 is a clinical study titled "Pazopanib in Combination With PCI-24781 in Patients With Metastatic Solid Tumors". This is a open-label non-randomized, dose escalation and expansion Phase Ia/Ib study to determine the safety, tolerability and maximum tolerated dose (MTD) of pazopanib in combination with PCI-24781 in patients with advanced solid tumors.
What is the current status of trial NCT01543763?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 90 participants. The study started on 2012-06-25. Estimated completion is 2024-12-31.
What interventions are being tested in trial NCT01543763?
The interventions under investigation include: PZP115891, PCI-24781 (DRUG).
Who is sponsoring clinical trial NCT01543763?
This trial is sponsored by Pamela Munster, which has 5 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.